J&J Stock Upgraded by Analysts Citing New Drugs

Leerink analysts upgraded Johnson & Johnson shares from hold to a buy equivalent, citing the company's promising slate of new drugs. This positive assessment comes in an AI-obsessed market, highlighting the value of traditional healthcare innovation.